VITA 34 AG: VITA 34 AG presents figures for third quarter 2012
VITA 34 AG / Key word(s): Quarter Results
30.10.2012 09:22
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
VITA 34 AG presents figures for third quarter 2012
- Revenues of 3.5m Euro
- EBITDA of 0.2m Euro
- Total annual forecast adjusted: Result expected to be below previous year
Leipzig, 30 October 2012 - VITA 34 AG (ISIN DE000A0BL849), the oldest
private umbilical cord blood bank in the German-speaking countries, VITA 34
AG (ISIN DE000A0BL849), publishes the figures for the third quarter of
2012. Because of depressed storage figures in the core markets of Germany
and Spain, revenues and result in the period under review were below the
previous year's level. The revenues in the third quarter of 2012 amounted
to EUR 3.5 million, in the wake of EUR 4.3 million in the previous year.
1,852 umbilical cord blood preparations were stored, following 2,363
preparations in the third quarter of 2011. The operating result (EBITDA)
was EUR 0.2 million, compared to EUR 0.5 million in the same period last
year. The net result amounted to EUR -0.1 million, following EUR 0.96
million. The operating figures cannot unrestrictedly be compared, as a
positive special item of some EUR 1 million resulting from the activation
of deferred taxes had incurred in the previous year.
In the first nine months of 2012, 5,570 umbilical cord blood preparations
were stored, compared to 6,840 preparations in the same period last year.
Revenues amounted to EUR 10.1 million, in the wake of EUR 12.1 million. The
EBITDA amounted to EUR 0.2 million, whereas EUR 0.3 million was achieved
last year. The net result amounted to EUR -0.5 million, following EUR 0.5
million and, adjusted for special items, EUR -0.5 million in the first nine
months of 2011.
It becomes apparent that revenues as well as the result in the fiscal year
2012 will respectively be below the previous year's level. So far, VITA 34
had expected revenues to be lower than in 2011, but had also assumed the
EBITDA to moderately increase. VITA 34 has already initiated measures to
reduce costs and improve profitability and now expects the EBITDA to
increase in 2013. The newly concluded cooperation agreements should have
positive effects. Costs are to be further reduced in the future and the
foreign business expanded. One focus will be placed on expanding the
product range in the future. VITA 34 has already laid the foundation for
this and, after the period under review had ended, developed the first GMP
(Good Manufacturing Practice) procedure worldwide, which allows for the
entire umbilical cord to be stored. The respective manufacturing license
for preparations from umbilical cord tissue pursuant to the German
Pharmaceuticals Act has already been applied for by VITA 34. We expect this
new product to contribute significantly to the revenues as of 2013.
The complete quarterly report will be available for download at
www.vita34group.de in the course of the day.
Press/Investor Relations:
Axel Mühlhaus
Peggy Kropmanns
edicto GmbH
Eschersheimer Landstr. 42-44
D-60322 Frankfurt
Phone:+49 (069) 90550550
Fax: +49 (069) 90550577
E-mail: vita34@edicto.de
30.10.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: VITA 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: info@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
